ACTH 1-17 effects in intrinsic bronchial asthma.
We have studied the effect of Synchrodyn 1-17 (100 micrograms/day/15 days, intramuscularly) on 12 patients with intrinsic asthma, presenting a circadian pattern in several functional parameters related to the bronchial patency (and/or with bouts of nocturnal asthma). Treatment with ACTH 1-17 had two main effects: the pathological rhythms of the bronchial tone disappeared and there was a clear general improvement in the indices of bronchial patency. The drug was well tolerated. Euphoria and water retention were the side effects: they were noticed in a variable number of subjects and disappeared after discontinuation of treatment.
D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002940:Circadian Rhythm; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*
D010446:Peptide Fragments; D000324:Adrenocorticotropic Hormone; C028238:ACTH (1-17)